AHA: Atrial Natriuretic Peptide Curbs Damage After Heart Attack
Infusion of carperitide reduces infarct size by nearly 15 percent and boosts ejection fraction
WEDNESDAY, Nov. 15 (HealthDay News) -- Atrial natriuretic peptide (carperitide), an acute heart failure treatment available in Japan, can reduce infarct size and increase left ventricular ejection fraction when used to treat acute myocardial infarction patients, according to a study presented at the American Heart Association's Scientific Sessions in Chicago.
Musafumi Kitakaze, M.D., Ph.D., of the National Cardiovascular Center in Suita, Japan, and colleagues reported results from J-WIND (Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP or Nicorandil). In the trial, 1,216 ST-segment elevation acute myocardial infarction patients were randomized to an infusion of carperitide or nicorandil in addition to standard treatment.
Patients treated with carperitide had a 14.7 percent reduction in infarct size and a 5.1 percent increase in ejection fraction, as well as a reduced risk of reperfusion injury, cardiac death and heart failure-related hospitalization. The same results were not seen with nicorandil. However, when nicorandil was taken orally during the chronic phase, it did improve left ventricular ejection fraction and reduce the development of new coronary lesions that required revascularization.
"These results will change the strategy of the acute-phase treatment of heart attack," said Kitakaze in a statement. The study was funded by grants from Japan's Ministry of Health, Labour and Welfare, as well as the Japan Cardiovascular Research Foundation.